RIGL - Rigel Pharmaceuticals, Inc.
| Previous Close | 2.62 |
| Open | 2.68 |
| Bid | 2.53 x 34100 |
| Ask | 2.72 x 3000 |
| Day's Range | 2.56 - 2.70 |
| 52 Week Range | 2.23 - 4.71 |
| Volume | 1,364,614 |
| Avg. Volume | 2,257,659 |
| Market Cap | 432.752M |
| Beta | 0.73 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.65 |
| Earnings Date | Jul 30, 2018 - Aug 3, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 7.92 |
- Motley Fool•12 days ago
Here's Why Rigel Pharmaceuticals, Inc. Rose as Much as 17.2% Today
The pharmaceutical company announced second-quarter 2018 earnings results.
- Zacks•13 days ago
Rigel Pharmaceuticals (RIGL) Reports Q2 Loss, Tops Revenue Estimates
Rigel (RIGL) delivered earnings and revenue surprises of 0.00% and 489.77%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•13 days ago
Rigel: 2Q Earnings Snapshot
On a per-share basis, the South San Francisco, California-based company said it had a loss of 16 cents. The results met Wall Street expectations. The average estimate of four analysts surveyed by Zacks ...
- PR Newswire•13 days ago
Rigel Announces Second Quarter 2018 Financial Results and Provides Company Update
$1.8 Million in Net Product Sales for TAVALISSE™ (fostamatinib disodium hexahydrate) Conference Call and Webcast Today at 5:00PM Eastern Time SOUTH SAN FRANCISCO, Calif. , Aug. 8, 2018 /PRNewswire/ -- Rigel ...
- ACCESSWIRE•13 days ago
Rigel Pharmaceuticals, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / August 8, 2018 / Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 8, 2018 at 5:00 PM Eastern ...
- PR Newswire•20 days ago
Rigel Announces Conference Call and Webcast to Report Second Quarter 2018 Financial Results
SOUTH SAN FRANCISCO, Calif. , Aug. 1, 2018 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) today announced that it will report its second quarter 2018 financial results after market close on ...
- ACCESSWIRE•21 days ago
Free Technical Reports on Sarepta Therapeutics and Three Additional Biotech Equities
LONDON, UK / ACCESSWIRE / July 31, 2018/ If you want a free Stock Review on SRPT sign up now at www.wallstequities.com/registration. Losses were broad based as seven out of nine sectors finished the trading session in red. WallStEquities.com has initiated research reports on the following Biotechnology stocks: Protalix BioTherapeutics Inc. (NYSE AMER: PLX), Radius Health Inc. (NASDAQ: RDUS), Rigel Pharmaceuticals Inc. (NASDAQ: RIGL), and Sarepta Therapeutics Inc. (NASDAQ: SRPT).
- Kiplinger•25 days ago
10 Strong Buy Stocks for Under $10
Just because a stock is cheap doesn't mean you should have to compromise on quality. These 10 Strong Buy stocks tick all the boxes. True, they are all trading for under $10, but they also represent compelling investing opportunities based on far more than just their price. I used TipRanks' stock screener to purposefully scan for stocks with a Strong Buy consensus rating from analysts and top analysts alike. These are stocks with a bullish Street outlook based only on the last three months of ratings. I then ordered the results by price in order to delve deeper into the cheaper stock results. I am confident that these 10 stocks provide intriguing investing opportunities for investors. You don't need to spend over $1,000 on a large-cap stock with a big name to generate serious investing returns. I hope these stellar stock ideas will show you why. Let's take a closer look now: SEE ALSO FROM KIPLINGER: 10 Cheap Stocks to Buy With Only $10
- GlobeNewswire•25 days ago
Recent Analysis Shows Synopsys, Rigel Pharmaceuticals, Fate Therapeutics, Philip Morris International, Sally Beauty, and Kimberly-Clark Market Influences — Renewed Outlook, Key Drivers of Growth
NEW YORK, July 27, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Synopsys, ...
- PR Newswire•2 months ago
Rigel Initiates Phase 1 Clinical Trial of R835, an IRAK1/4 Inhibitor for Autoimmune and Inflammatory Diseases
SOUTH SAN FRANCISCO, Calif., June 26, 2018 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (RIGL) today announced that it has initiated a Phase 1 study to assess safety, tolerability, pharmacokinetics and pharmacodynamics of R835 in healthy subjects. Rigel selected R835, a proprietary molecule from its interleukin receptor associated kinase (IRAK) preclinical development program, for human clinical trials. Preclinical studies show that R835 inhibits both the IRAK1 and IRAK4 signaling pathways, which play a key role in inflammation and immune responses to tissue damage.
- PR Newswire•2 months ago
Rigel Announces Poster Presentations at FOCIS Annual Meeting
SOUTH SAN FRANCISCO, Calif. , June 20, 2018 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Dr. Anne-Marie Duliege, Chief Medical Officer, will be presenting two posters ...
- ACCESSWIRE•2 months ago
Rigel Pharmaceuticals Wins FDA Approval, Potential Clinical Catalysts and Analyst Review
NEW YORK, NY / ACCESSWIRE / June 18, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Rigel Pharmaceuticals, Inc., (RIGL), a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company recently announced that TAVALISSE™ (fostamatinib disodium hexahydrate) is available by prescription for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to previous treatment.
- PR Newswire•2 months ago
Rigel To Present Phase 2 Results for Fostamatinib in Autoimmune Hemolytic Anemia at EHA
SOUTH SAN FRANCISCO, Calif. , June 12, 2018 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will be presenting an oral presentation on the Phase 2 Stage 1 interim results ...
- PR Newswire•3 months ago
Rigel to Present at Jefferies 2018 Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif. , May 31, 2018 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez , the company's president and chief executive officer, is scheduled ...
- Benzinga•3 months ago
Benzinga's Daily Biotech Pulse: Chinese Cheer For Gilead, Immutep Presents Positive Phase 1 Data, FDA Accepts Exelixis sNDA
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech stocks hitting 52-week highs on May 29) Ascendis Pharma A/S (NASDAQ: ASN ) ASLAN PHARMACEUTICALS ...
- PR Newswire•3 months ago
Rigel Appoints Dean Schorno as Chief Financial Officer
SOUTH SAN FRANCISCO, Calif. , May 30, 2018 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it has appointed Dean Schorno , CPA as Executive Vice President and Chief Financial ...
- PR Newswire•3 months ago
Rigel Announces Availability of TAVALISSE™ (fostamatinib disodium hexahydrate) in the U.S.
Launches RIGEL ONECARE™ to Support Patients and Providers SOUTH SAN FRANCISCO, Calif. , May 29, 2018 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today announced that TAVALISSE™ (fostamatinib ...
- Thomson Reuters StreetEvents•3 months ago
Edited Transcript of RIGL earnings conference call or presentation 1-May-18 9:00pm GMT
Q1 2018 Rigel Pharmaceuticals Inc Earnings Call
- Benzinga•4 months ago
Benzinga's Daily Biotech Pulse: SIGA Rallies On FDA Panel Backing, Rigel And Gilead React To Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on May 1) ABIOMED, Inc. (NASDAQ: ABMD ) AveXis Inc (NASDAQ: AVXS ) (announced ...
- Associated Press•4 months ago
Rigel: 1Q Earnings Snapshot
On a per-share basis, the South San Francisco, California-based company said it had a loss of 17 cents. The results met Wall Street expectations. The average estimate of three analysts surveyed by Zacks ...
- PR Newswire•4 months ago
Rigel Announces First Quarter 2018 Financial Results and Provides Company Update
Rigel Expected to Launch TAVALISSE™ (fostamatinib disodium hexahydrate) in the U.S. in late May 2018 Conference Call and Webcast Today at 5:00PM Eastern Time SOUTH SAN FRANCISCO, Calif. , May 1, 2018 /PRNewswire/ ...
- PR Newswire•4 months ago
TAVALISSE™ (fostamatinib disodium hexahydrate) Phase 3 Data Published in the American Journal of Hematology Describes Pivotal Data and Overall Response Rate Versus Placebo
SOUTH SAN FRANCISCO, Calif. , April 30, 2018 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that the American Journal of Hematology has published positive results from the Fostamatinib ...
- PR Newswire•4 months ago
Rigel Announces Pricing Of Public Offering Of Common Stock
SOUTH SAN FRANCISCO, Calif. , April 19, 2018 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the pricing of its previously announced underwritten public offering of 16,000,000 ...
- Motley Fool•4 months ago
Why Bank of New York Mellon, Snap-on, and Rigel Pharmaceuticals Jumped Today
Learn how these stocks defied a down market.
- PR Newswire•4 months ago
Rigel Announces Proposed Public Offering Of Common Stock
SOUTH SAN FRANCISCO, Calif., April 18, 2018 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (RIGL) today announced that it intends to offer and sell up to 15,000,000 shares of its common stock in an underwritten public offering. Rigel expects to grant the underwriters a 30-day option to purchase up to an additional 2,250,000 shares of common stock sold in the public offering on the same terms and conditions. All of the shares to be sold in the offering are to be sold by Rigel, with the proceeds to be used for activities in connection with the commercial launch of TAVALISSE in the United States, research and development and general corporate purposes.
